lapatinib has been researched along with Neoplasms, Squamous Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhury, A; Fujii, H; Inoue, M; Izawa, S; Kawaguchi, Y; Kiessling, R; Kono, K; Kono, T; Maruyama, T; Mimura, K; Mizukami, Y; Shiba, S; Watanabe, M | 1 |
| Biswas-Baldwin, N; Bourhis, J; Carracedo, C; Compton, N; Cupissol, D; De Raucourt, D; Del Campo, JM; Downie, L; El-Hariry, I; Harrington, KJ; Hitt, R; Lokanatha, D; Maroudias, N; Midwinter, D; Nutting, CM; Sebastian, P; Temam, S | 1 |
1 trial(s) available for lapatinib and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Disease Progression; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Squamous Cell; Placebos; Quinazolines; Single-Blind Method; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2011 |
1 other study(ies) available for lapatinib and Neoplasms, Squamous Cell
| Article | Year |
|---|---|
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Genes, erbB-2; Humans; Lapatinib; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2011 |